

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Title: Projected Impact of Nonpharmacologic Management of Stage 1 Hypertension Among Lower-Risk US Adults

Short Title: Nonpharmacologic Management of Hypertension

Kendra D. Sims, PhD, MPH*^{1,2}; Pengxiao Carol Wei, MPH*¹; Joanne M. Penko, MS, MPH¹; Susan Hennessy, PhD¹; Pamela G. Coxson, PhD¹; Nita H. Mukand, PharmD, MBA, MPH¹; Brandon K. Bellows, PharmD, MS³; Dhruv S. Kazi, MD, MSc, MS⁴; Yiyi Zhang, PhD³; Ross Boylan, PhD¹; Andrew E. Moran, MD, MPH³; Kirsten Bibbins-Domingo, PhD, MD, MAS^{1,5,6,7}

*these authors contributed equally as first authors to this work

Affiliations:

1. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
2. Department of Epidemiology, Boston University School of Public Health, Boston, MA
3. Department of Medicine, Division of General Medicine, Columbia University Irving Medical Center, New York, New York
4. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts
5. Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, San Francisco, California
6. UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital, San Francisco, California
7. Editorial Board, Journal of the American Medical Association, Chicago, Illinois

Address for correspondence:

Kendra D. Sims, PhD
Boston University School of Public Health
715 Albany St, Boston, MA 02118
Phone: (617) 358-3301 | Email: ksims17@bu.edu

Word count: 2847

39 **Abstract**

40 **Background:** The 2017 American College of Cardiology (ACC)/American Heart Association
41 (AHA) guidelines newly classified 31 million US adults as having stage 1 hypertension. The
42 ACC/AHA guidelines recommend behavioral change without pharmacology for the low-risk
43 portion of this group. However, the nationwide reduction in cardiovascular disease (CVD) and
44 associated healthcare expenditures achievable by evidence-based dietary improvements,
45 sustained weight loss, adequate physical activity, and alcohol moderation remain unquantified.
46 We estimated the effect of systolic BP (SBP) control and behavioral changes on 10-year CVD
47 outcomes and costs.

48 **Methods:** We used the CVD Policy Model to simulate CVD events, mortality, and healthcare
49 costs among US adults aged 35-64. We simulated interventions on a target population, identified
50 from the 2015-2018 National Health and Nutrition Examination Survey, with low-risk stage 1
51 systolic hypertension: defined as untreated SBP 130-139 mmHg and diastolic BP <90 mmHg; no
52 history of CVD, diabetes, or chronic kidney disease; and low 10-year risk of CVD. We used
53 published meta-analyses and trials to estimate the effects of behavior modification on SBP. We
54 assessed the extent to which intermittent healthcare utilization or partial uptake of
55 nonpharmacologic therapy would decrease CVD events prevented.

56 **Results:** Controlling SBP to <130 mmHg among the estimated 8.8 million U.S. adults (51%
57 women) in the target population could prevent 26,100 CVD events, avoid 2,900 deaths, and save
58 \$1.6 billion in healthcare costs over 10 years. The Dietary Approaches to Stop Hypertension
59 (DASH) diet could prevent 16,000 CVD events among men and 12,000 among women over a
60 decade. Other nonpharmacologic interventions could avert between 3,700 and 19,500 CVD
61 events. However, only 5.5 million (61%) of the target population regularly utilized healthcare
62 where recommended clinician counseling could occur.

63 **Conclusions:** As only two-thirds of U.S. adults with Stage 1 hypertension regularly receive
64 medical care, substantial benefits to cardiovascular health and associated costs may only stem
65 from policies that promote widespread adoption and sustained adherence of nonpharmacologic
66 therapy. Future work should quantify the population-level costs, benefits, and efficacy of
67 improving the food system and local infrastructure on health behavior change.

68

69

70

71

72

73

74

75

76 **Clinical Perspective:**

77 **What is new? (<100 words)**

- 78 • Guidelines recommend modifying health behaviors to achieve blood pressure control in
79 individuals with stage 1 hypertension, but the nationwide reduction in cardiovascular
80 disease (CVD) and associated healthcare expenditures achieved remain unquantified.
- 81 • Using a public policy simulation model of CVD, we projected that controlling stage 1
82 systolic hypertension with nonpharmacologic therapy among an initially low-risk
83 population of nearly 9 million young- and middle-aged adults would avert approximately
84 26,000 CVD events, 3000 deaths, and \$1.6 billion in healthcare costs over 10 years.
- 85 • The Dietary Approaches to Stop Hypertension (DASH) diet could provide the greatest
86 population benefit.

87

88 **What are the clinical implications? (<100 words)**

- 89 • Evidence-based health behaviors, such as adopting the unprocessed foods-centric Dietary
90 Approaches to Stop Hypertension (DASH) diet, could provide long-term dividends to
91 improved cardiovascular health.
- 92 • However, one-third of initially low-risk adults with stage 1 hypertension did not regularly
93 use healthcare. There additionally are documented challenges to sustaining these lifestyle
94 changes. Systemic deprivation of health-promoting resources in the social and built
95 environment can pose insurmountable economic barriers for marginalized patients,
96 perpetuating cardiovascular disparities.
- 97 • The recommended medical provider counseling on behavioral modification must be
98 paired with community interventions, infrastructure improvements, and nutrition-
99 promoting food system policies to promote adherence.

100

101

102

103

104

105

106 **Keywords:** cardiovascular disease, hypertension, clinical guidelines, public policy, behavioral
107 intervention

108 **Non-standard Abbreviations and Acronyms:** ACC/AHA, American College of Cardiology
109 and American Heart Association (ACC/AHA); SBP, systolic blood pressure; DBP, diastolic
110 blood pressure; DASH, Dietary Approaches to Stop Hypertension; NHANES, National Health
111 and Nutrition Examination Survey

112 **Introduction**

113 The 2017 American College of Cardiology and American Heart Association (ACC/AHA)
114 guidelines reinforced the importance of blood pressure (BP) control for disease prevention by
115 lowering the hypertensive threshold¹. Compared with the Seventh Report of the Joint National
116 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7)
117 BP classification, the ACC/AHA guidelines newly categorizes 31 million US adults as having
118 stage 1 hypertension (systolic BP [SBP]/diastolic BP [DBP] 130/80-139/89 mmHg)^{2,3}.
119 However, the guidelines recommend pharmacotherapy only for the small subset of this group
120 who are 65 years and older, have a history of cardiovascular disease (CVD), diabetes, chronic
121 kidney disease, or a 10-year risk of CVD of at least 10 percent. For the rest of this patient base,
122 clinicians are instead advised to provide counseling on lifestyle changes based on findings from
123 short-term behavioral intervention trials⁴. These nonpharmacologic therapies include the Dietary
124 Approaches to Stop Hypertension (DASH) diet⁵, sufficient physical activity⁶, balancing dietary
125 intake of potassium to sodium⁷, sustaining loss of excess body weight⁸, and ceasing excessive
126 alcohol consumption⁹. The potential long-term population health and economic benefits of
127 scaling up behavioral intervention trial findings for the population with stage 1 hypertension not
128 recommended pharmacotherapy remain unquantified¹⁰. Additionally, the extent to which lack of
129 regular healthcare access might limit opportunities to identify stage 1 hypertension and counsel
130 nonpharmacologic therapies that prevent CVD has not been ascertained for this group.

131 Using a public policy simulation model of CVD and data from the National Health and
132 Nutrition Examination Survey (NHANES), we first described the US adult population with stage
133 1 systolic hypertension (SBP 130-139 mmHg and DBP <90 mmHg) who would be
134 recommended only nonpharmacologic therapy by the 2017 ACC/AHA BP guideline. We then

135 projected the effect of SBP control via nonpharmacological therapy on CVD incidence, CVD
136 mortality, and healthcare costs over 10 years. We also assessed the attenuated impact of
137 recommended medical provider counseling on nonpharmacologic therapy in this population due
138 to lack of regular healthcare utilization.

139

140 **Methods**

141 **Model overview**

142 The CVD Policy Model is a state-transition computer simulation model of coronary heart
143 disease (CHD) and stroke incidence, recurrence, mortality, and direct healthcare costs in all US
144 adults aged 35-94 years¹¹⁻¹⁵. Core model inputs are estimated from nationally representative
145 databases, longitudinal cohort studies, and natural history studies (Supplemental Table S2). For
146 the population without CVD, the model predicts the annual incidence of CHD, stroke, and non-
147 CVD mortality via competing risk models. We base estimates on age, sex, and CVD risk factors,
148 using risk functions calculated from data pooled and harmonized from several National Heart,
149 Lung, and Blood Institute (NHLBI) observational cohorts¹⁶⁻²⁰. The population distribution of
150 CVD risk factors (i.e., SBP, DBP, self-reported use of antihypertensive medications, low- and
151 high-density lipoprotein cholesterol, exposure to tobacco smoke, and diabetes status) are derived
152 from the NHANES 2015-2016 and 2017-2018 cycles²¹. By incorporating expected population
153 growth as well as changes in risk factors and event rate, the model projects subsequent CVD
154 events, coronary revascularization procedures, and mortality from CVD and non-CVD causes in
155 annual cycles (Supplemental Figure S1). Direct healthcare costs associated with acute CVD
156 events are derived from the National Inpatient Sample (NIS) and costs associated with chronic
157 CVD and background (non-CVD) healthcare are derived from the Medical Expenditure Panel

158 Survey (MEPS)^{22,23}. The model was calibrated to reproduce annual CVD event rates within 1%
159 of observed hospital discharges in NIS (2012-2016) and deaths observed in US National Vital
160 Statistics System (2018)^{22,24,25}. The study was considered exempt by the Institutional Review
161 Board at the University of California, San Francisco. We followed the Consolidated Health
162 Economic Evaluation Reporting Standards (CHEERS) reporting guideline for health economic
163 evaluations²⁶.

164

165 **Model inputs and target population**

166 Key model inputs are described in Supplemental Table S2. The target population is US
167 adults aged 35-64 years with untreated stage 1 systolic hypertension (SBP 130-139 mmHg and
168 DBP <90 mmHg) for whom only nonpharmacological therapy (e.g., dietary changes, increasing
169 physical activity, weight loss) is recommended by the 2017 ACC/AHA BP guideline¹. We
170 limited our study to stage 1 systolic hypertension due to insufficient evidence for
171 nonpharmacologic therapy on DBP on CVD outcomes or long-term CVD outcomes associated
172 with stage 1 isolated diastolic hypertension (SBP <130 mmHg and DBP 80-89 mmHg)²⁷. The
173 mean of all available measures for each NHANES participant was used for BP. Operationally,
174 we used the subsample of NHANES of appropriate age and blood pressure ranges; no reported
175 current medications to treat high BP; no history of CVD, diabetes, or chronic kidney disease; and
176 the contemporaneous criteria for <10% predicted risk of a CVD event in 10 years²⁸
177 (Supplemental Table S3).

178 Based on current US guidelines for physical activity²⁹ and diet³⁰, we estimated the
179 proportion of men and women in the target population who are insufficiently active (<600
180 metabolic equivalent minutes of task [METS] per week), overweight or obese (body mass index

181 [BMI] ≥ 25 kg/m²), and who consume excessive sodium (≥ 2300 mg/day), inadequate potassium
182 (<3400 mg/day for men; <2600 mg/day for women), lower than recommended amounts of fruits
183 and vegetables (<2 cups of fruit and/or <2.5 cups of vegetables per day), and excessive alcohol
184 (>2 drinks/day for men; >1 drink/day for women; 14 grams of alcohol = 1 drink). We assumed
185 that no one in the target population adhered to the DASH diet based on low reported intake of
186 fruits and vegetables and excessive sodium in NHANES. We implemented a classification of
187 regular access to healthcare previously used in NHANES³¹, based on participants confirming
188 having some form of health insurance, at least one routine place they receive healthcare, and at
189 least one visit to a healthcare professional in a non-emergency room context in the past year.

190

191 **Simulated comparators**

192 We simulated a baseline “status quo” scenario that incorporated SBP changes expected
193 with demographic shifts as the target population ages. We compared the status quo with the
194 mean SBP reduction from trial and meta-analysis data of nonpharmacological management
195 among individuals in the target population not meeting recommended thresholds for specific
196 health behaviors (Supplemental Table S1). Adopting the DASH dietary pattern reduced SBP by
197 5.5 mmHg³². Sustained weight loss among adults with a BMI ≥ 25 kg/m² reduced SBP by 4.8
198 mmHg³³. Reduced dietary sodium among adults with excessive intake reduced SBP by 4.2
199 mmHg³⁴. Increased fruit and vegetable consumption among adults with insufficient dietary
200 potassium reduced SBP by 2.8 mmHg³². Adequate physical activity among adults who do not
201 engage in sufficient weekly METS reduced SBP by 3.8 mmHg³⁵. Reduced alcohol consumption
202 among adults consuming more than recommended drinks weekly reduced SBP by 3.1 mmHg³⁶.
203 The total population effect of an intervention was therefore dependent both on the size of the

204 SBP reduction and number of individuals exhibiting the modifiable risk. Since the mean SBP in
205 the target population overall is less than 4 mmHg above 130 for both men and women, some of
206 these effect sizes reduced blood pressure below the 129 SBP target assumed in the initial
207 analysis. As trial and meta-analysis data of nonpharmacological management did not quantify
208 either selection into their studies or long-term adherence, we simulated in sensitivity analyses
209 control to 129 SBP assuming 50% of the intervenable target population adhered to each
210 intervention over 10 years.

211 We also compared the “status quo” scenario with a scenario controlling SBP to <130
212 mmHg (i.e., max SBP set to 129 mmHg) each year for all individuals in the target population.
213 We conservatively assumed that those whose risk factor profile changed so that they would be
214 eligible for pharmacological intervention according to the 2017 ACC/AHA BP guideline (e.g.,
215 developed diabetes) would initiate medications, resulting in an SBP <130 mmHg with no change
216 to their other risk factors. We also simulated controlled SBP <130 mmHg only among those with
217 regular access to healthcare. This set of analyses assessed the full benefit of the entire target
218 population achieving the goals outlined by the 2017 ACC/AHA guidelines, as well as how
219 focusing on counseling in the healthcare setting would attenuate the extent of CVD events
220 prevented and healthcare costs saved.

221

222 **Statistical analyses**

223 We simulated a nationally representative dynamic cohort of US adults over 10 years,
224 starting in 2018 and running through 2027. For each intervention, we calculated the difference in
225 (1) incident and total CVD events, (2) CVD mortality, and (3) associated direct healthcare costs

226 relative to the status quo. Using Monte Carlo methods, we repeated the analyses 1000 times,
227 randomly selecting model input parameters with replacement from pre-specified distributions
228 scaled to the mean and confidence interval (Supplemental Table S3) and generated 95%
229 uncertainty intervals around model estimates. We used normal distributions for baseline SBP and
230 mean SBP changes expected for nonpharmacologic therapy^{21,32-36}; lognormal distributions for
231 the relative risks of CHD, ischemic stroke, and hemorrhagic stroke associated with SBP changes
232³⁷; and lognormal distributions for healthcare utilization costs^{22,23}.

233 The CVD Policy Model is programmed using the Intel Fortran Compiler Classic 2021.5
234 and Monte Carlo simulations are run using Python version 3.10. We estimated model inputs
235 using Stata 17 and SAS version 9.4 and analyzed outcomes using Microsoft Excel version 2108.

236

237 **Results**

238 The simulated target population represents an estimated 4.2 million men and 4.6 million
239 women aged 35-64 years. Table 1 presents the gender-stratified clinical and behavioral
240 characteristics. Only 40% reported adequate intake of fruits and vegetables. Four-fifths had a
241 BMI classified as either overweight or obese. Men were more likely than women to consume
242 excess sodium (92% versus 71%) and alcohol (28% versus 17%). Insufficient physical activity
243 was more prevalent among women than men (45% versus 30%). Only 51% of men and 73% of
244 women in the target population were both insured and had visited their routine, non-emergency
245 healthcare provider within the past year.

246 By focusing on stage 1 systolic hypertension, we target approximately half of the total
247 population for whom the ACC/AHA 2017 guidelines recommend behavioral change. These

248 guidelines would classify an additional 3.9 million men and 3.2 million women at low-CVD risk
249 as having stage 1 isolated diastolic hypertension (Supplemental Table S4).
250 Compared with the status quo among US adults with stage 1 hypertension recommended
251 nonpharmacologic therapy, controlling SBP to 129 mmHg is projected to prevent 26,100 (95%
252 CI: 22,600 – 30,700) incident CVD events and 2,900 (95% CI: 2,400 – 3,300) CVD deaths over
253 10 years (Table 2). Averting these CVD events and mortality would save an estimated \$1.6 (95%
254 CI: \$1.4 – \$1.9) billion in hospitalizations, procedures, outpatient care, and background
255 healthcare costs. Figure 1 displays how not intervening among men and women who did not
256 regularly utilize healthcare would reduce incident CVD events prevented by each evidence-based
257 intervention by 39%. By intervening only via provider counseling, the projected number of CVD
258 events and CVD deaths prevented by controlling SBP to <130 mmHg was reduced, respectively,
259 to 15,800 (95% CI: 13,800 – 18,600) and 1,800 (95% CI: 1,600 – 2,000).

260 Full adoption of the DASH diet is the nonpharmacologic therapy that would translate to
261 the greatest mean SBP reduction, preventing a projected 28,000 (95% CI: 18,100 – 38,400) CVD
262 events and saving \$1.8 (95% CI: \$1.2 – \$2.4) billion in healthcare costs (Table 3, Figure 1).
263 Implementing an intervention that sustained weight loss would prevent 19,500 (95% CI: 15,200
264 – 24,200) CVD events over 10 years. The other nonpharmacologic therapies are projected
265 prevent thousands of CVD events and mortality, with hundreds of millions of dollars in
266 healthcare savings. We quantified in Supplemental Figure S2 the magnitude to which health and
267 economic benefit would be drastically attenuated by only achieving 50% adherence of each
268 intervention.

269

270

271 **Discussion**

272 Nearly 9 million US adults aged 35-64 years with stage 1 systolic hypertension would be
273 recommended nonpharmacological therapy by the 2017 ACC/AHA BP guideline because of
274 younger age and lower CVD risk. We projected that controlling SBP to <130 mmHg could
275 prevent over 26,000 CVD events compared with the status quo. Universal adoption of the DASH
276 diet was projected to prevent 28,000 CVD events over 10 years. Sustained weight loss, sodium
277 reduction, and increased fruit and vegetable intake could also offer significant population
278 benefits. Finally, relying solely on behavioral counseling at healthcare encounters might fail to
279 reach the half of men and one-quarter of women with stage 1 systolic hypertension at low CVD
280 risk who do not regularly engage with the healthcare system.

281 As the JNC7 BP guideline explicitly stated prehypertension was not a disease category¹,
282 the lower BP threshold to define hypertension in the 2017 ACC/AHA BP guideline is an
283 example of medicalization that effectively created a new medical diagnosis for those previously
284 considered disease-free³⁸. A new diagnosis of hypertension may change incentives in physician-
285 patient interactions. However, many providers have limited training in in effective health
286 counseling, let alone in tailoring recommendations for diverse patient populations³⁹. A common
287 critique of medicalization is that racial and ethnic minorities and people of lower socioeconomic
288 status (SES) face more barriers that prevent them from fulfilling these ‘prescribed’ health
289 behavior changes. Furthermore, the population most in need of nonpharmacological BP control
290 is often uninsured, and does not regularly access healthcare for counseling opportunities to
291 occur⁴⁰.

292 Policies that improve the food system and neighborhood conditions may facilitate
293 recommended behavior changes irrespective of whether a person regularly interacts with a
294 healthcare provider. Though salt alternatives can provide a more favorable ratio of dietary
295 potassium to sodium among those who cook at home⁴¹ population benefits may be minimal
296 among groups reliant on processed foods without commitment from stakeholders in restaurant
297 and food manufacturing industries⁴². The US Food and Drug Administration has recently
298 announced voluntary sodium reduction guidelines for commercially produced and packaged
299 foods, involving gradually reducing maximum sodium content to allow consumer tastes to adapt
300 and focusing on per-package versus per-serving sodium content⁴³. Similar industry-oriented
301 policies in the United Kingdom were associated with modest annual reductions in sodium levels
302 detected in population-representative urine samples between 2003 and 2007⁴⁴.

303 Community members are more likely to be more physically active if they reside in
304 economically invested areas that are well-connected by sidewalks, with adequate street lighting
305 and lower levels of crime^{45,46}. Amenities within walking distance that have been associated with
306 lower prevalence of physical inactivity and obesity include destinations for errands, green spaces
307 such as parks, outdoor features such as beaches and trails, and a public transit system that is
308 proximate to employment^{47,48}. Racial and ethnic minorities as well as low socioeconomic status
309 people are concentrated in areas with more barriers to walking, fewer free physical activity
310 facilities, and limited available healthy food choices^{46,49}. Marginalized people also often report
311 having less time and resources to engage in recommended health behaviors⁵⁰. Multilevel public
312 health strategies that restructure the disadvantaged environmental context for vulnerable groups
313 are vital to redress CVD disparities. These public health approaches can synergistically achieve a
314 broader population reach than the individual behavior change interventions that provided inputs

315 for our analysis. Quantifying the cost of such population-level interventions would enable
316 estimation of cost-effectiveness.

317

318 **Limitations**

319 Our study integrated several nationally representative data sources into a platform that
320 simulated the future impact of potential population-level interventions on blood pressure control.
321 However, NHANES only provides participant self-report of health behaviors such as diet and
322 physical activity, which may be subject to reporting bias. We modeled 50% and 100% uptake of
323 each nonpharmacological intervention and assumed sustained SBP reduction over 10 years,
324 which may be difficult to achieve in practice. Our results may therefore represent projections of
325 the upper limit of population benefits with independent interventions. We used meta-analysis and
326 trial results to simulate SBP reductions with nonpharmacologic therapy, where information on
327 long-term adherence was unavailable. Though our methods could only simulate the independent
328 impact of each intervention, nonpharmacological SBP management realistically necessitates a
329 combination of health behaviors: e.g., weight reduction via sufficient exercise in conjunction
330 with dietary modification. Our analysis only included individuals with stage 1 hypertension
331 according to the 2017 ACC/AHA BP guideline; however, if implemented population-wide,
332 nonpharmacological therapy could have even greater benefit by preventing CVD events among
333 individuals with normal and elevated BP as well as patients already on antihypertensive therapy.

334

335 **Conclusions**

336 We used a computer simulation model to project the potential health and economic
337 benefits of implementing evidence-based nonpharmacological therapy among nearly 9 million
338 US adults with stage 1 systolic hypertension. Each intervention has the potential to prevent
339 between 3,700 and 28,000 CVD events. Full adherence of the DASH diet could save up to 3,100
340 lives and avert upwards of \$1.7 billion in healthcare costs over 10 years. However, as only two-
341 thirds of these individuals regularly interact with the healthcare system, achieving the full benefit
342 via recommended provider counseling may remain elusive. Even among those in care,
343 marginalized people systematically lack the individual- or community-level resources needed to
344 modify their health behavior. For maximal population benefit, food system policies that improve
345 accessibility to nutrient-rich food as well as lower sodium choices will facilitate large-scale
346 adoption. Policymakers, industry stakeholders, and medical professionals need to collaborate on
347 strategies to manage blood pressure among this large group of adults vulnerable to long-term
348 CVD risk. Broad public health interventions on the local and federal infrastructure would likely
349 result in substantial benefits not only for adults with Stage 1 hypertension, but for the U.S.
350 population at large.

351

352

353

354

355

356

357 **Disclosures:** None

358 **Funding statement:** This work was funded by National Institutes of Health grant
359 K99AG083121 (PI: Sims)

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377 References

- 378 1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM,
379 Gidding S, Jamerson KA, Jones DW, et al. 2017
380 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
381 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of
382 the American College of Cardiology/American Heart Association Task Force on Clinical Practice
383 Guidelines. *Journal of the American College of Cardiology*. 2018;71:e127–e248.
- 384 2. Ritchey MD, Gillespie C, Wozniak G, Shay CM, Thompson-Paul AM, Loustalot F, Hong Y.
385 Potential need for expanded pharmacologic treatment and lifestyle modification services under the
386 2017 ACC/AHA Hypertension Guideline. *J Clin Hypertens (Greenwich)*. 2018;20:1377–1391.
- 387 3. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, Whelton PK. Potential U.S.
388 Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. *Journal of the American*
389 *College of Cardiology*. 2018;71:109–118.
- 390 4. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioral Counseling to Promote a
391 Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without
392 Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive
393 Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US);
394 2017 [cited 2021 Dec 12]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK476368/>
- 395 5. Schwingshackl L, Chaimani A, Schwedhelm C, Toledo E, Püsch M, Hoffmann G, Boeing H.
396 Comparative effects of different dietary approaches on blood pressure in hypertensive and pre-
397 hypertensive patients: A systematic review and network meta-analysis. *Crit Rev Food Sci Nutr*.
398 2019;59:2674–2687.
- 399 6. Barone Gibbs B, Hivert M-F, Jerome GJ, Kraus WE, Rosenkranz SK, Schorr EN, Spartano NL,
400 Lobelo F, null null. Physical Activity as a Critical Component of First-Line Treatment for Elevated
401 Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American
402 Heart Association. *Hypertension*. 2021;78:e26–e37.
- 403 7. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood
404 Pressure. *Hypertension*. 2016;67:733–739.
- 405 8. Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo
406 D, et al. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific
407 Statement From the American Heart Association. *Hypertension*. 2021;78:e38–e50.
- 408 9. Aladin AI, Chevli PA, Ahmad MI, Rasool SH, Herrington DM. Alcohol Consumption and Systemic
409 Hypertension (from the Third National Health and Nutrition Examination Survey). *The American*
410 *Journal of Cardiology*. 2021;160:60–66.
- 411 10. Jones DW, Whelton PK, Allen N, Clark D, Gidding SS, Muntner P, Nesbitt S, Mitchell NS,
412 Townsend R, Falkner B, et al. Management of Stage 1 Hypertension in Adults With a Low 10-Year
413 Risk for Cardiovascular Disease: Filling a Guidance Gap: A Scientific Statement From the
414 American Heart Association. *Hypertension*. 2021;77:e58–e67.

- 415 11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on
416 Cost-Effectiveness in Health and Medicine. *JAMA*. 1996;276:1253–1258.
- 417 12. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L,
418 Bibbins-Domingo K, Coxson PG, Goldman L. Cost-Effectiveness of Hypertension Therapy
419 According to 2014 Guidelines. *N Engl J Med*. 2015;372:447–455.
- 420 13. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D,
421 Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous
422 Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. *JAMA*. 2016;316:743–
423 753.
- 424 14. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J,
425 Weinstein MC. The recent decline in mortality from coronary heart disease, 1980-1990. The effect
426 of secular trends in risk factors and treatment. *JAMA*. 1997;277:535–542.
- 427 15. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent Overweight and
428 Future Adult Coronary Heart Disease. *New England Journal of Medicine*. 2007;357:2371–2379.
- 429 16. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacobs Jr.
430 DR, Kronmal R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and Design.
431 *American Journal of Epidemiology*. 2002;156:871–881.
- 432 17. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA,
433 Mittelmark MB, Newman A, et al. The cardiovascular health study: Design and rationale. *Annals of*
434 *Epidemiology*. 1991;1:263–276.
- 435 18. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, Liu K, Savage PJ.
436 Cardia: study design, recruitment, and some characteristics of the examined subjects. *Journal of*
437 *Clinical Epidemiology*. 1988;41:1105–1116.
- 438 19. KANNEL WB, FEINLEIB M, McNAMARA PM, GARRISON RJ, CASTELLI WP. AN
439 INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES: THE FRAMINGHAM
440 OFFSPRING STUDY. *American Journal of Epidemiology*. 1979;110:281–290.
- 441 20. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E, Newman
442 AB. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. *Journal of*
443 *Applied Physiology*. 2001;90:2157–2165.
- 444 21. National Health and Nutrition Examination Survey, 2015–2018 : sample design and estimation
445 procedures [Internet]. [cited 2023 Apr 11]; Available from: <https://stacks.cdc.gov/view/cdc/88305>
- 446 22. HCUP-US NIS Overview [Internet]. [cited 2022 Oct 11]; Available from: [https://www.hcup-](https://www.hcup-us.ahrq.gov/nisoverview.jsp)
447 [us.ahrq.gov/nisoverview.jsp](https://www.hcup-us.ahrq.gov/nisoverview.jsp)
- 448 23. Medical Expenditure Panel Survey Home [Internet]. [cited 2023 Apr 11]; Available from:
449 <https://meps.ahrq.gov/mepsweb/>
- 450 24. Gacutan K. HEALTHCARE COST AND UTILIZATION PROJECT — HCUP. 2020;53.

- 451 25. Underlying Cause of Death 1999-2020 [Internet]. [cited 2023 Jan 30]; Available from:
452 <https://wonder.cdc.gov/wonder/help/ucd.html#>
- 453 26. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
454 Chaiyakunapruk N, Greenberg D, Loder E, et al. Consolidated Health Economic Evaluation
455 Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health
456 economic evaluations. *BMC Medicine*. 2022;20:23.
- 457 27. McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM,
458 Coresh J, Selvin E. Association of Isolated Diastolic Hypertension as Defined by the 2017
459 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. *JAMA*.
460 2020;323:329–338.
- 461 28. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P,
462 Lackland DT, Levy D, O’Donnell CJ, et al. 2013 ACC/AHA Guideline on the Assessment of
463 Cardiovascular Risk. *Circulation*. 2014;129:S49–S73.
- 464 29. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. :779.
- 465 30. Dietary Guidelines for Americans, 2020-2025.
- 466 31. Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension Control in the United
467 States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age-
468 and Race-Ethnicity Groups. *Hypertension*. 2021;78:578–587.
- 469 32. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM,
470 Cutler JA, Windhauser MM, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood
471 Pressure. *N Engl J Med*. 1997;336:1117–1124.
- 472 33. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of Weight Reduction on Blood
473 Pressure: A Meta-Analysis of Randomized Controlled Trials. *Hypertension*. 2003;42:878–884.
- 474 34. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure.
475 *Cochrane Database Syst Rev*. 2013;CD004937.
- 476 35. Whelton SP, Chin A, Xin X, He J. Effect of Aerobic Exercise on Blood Pressure. *Ann Intern Med*.
477 2002;136:493–503.
- 478 36. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in
479 alcohol consumption on blood pressure: a systematic review and meta-analysis. *The Lancet Public*
480 *Health*. 2017;2:e108–e120.
- 481 37. Zhang Y, Vittinghoff E, Pletcher MJ, Allen NB, Zeki Al Hazzouri A, Yaffe K, Balte PP, Alonso A,
482 Newman AB, Ives DG, et al. Associations of Blood Pressure and Cholesterol Levels During
483 Young Adulthood With Later Cardiovascular Events. *J Am Coll Cardiol*. 2019;74:330–341.
- 484 38. Lantz PM. The Medicalization of Population Health: Who Will Stay Upstream? *The Milbank*
485 *Quarterly*. 2019;97:36.
- 486 39. Kris-Etherton PM, Petersen KS, Després J-P, Anderson CAM, Deedwania P, Furie KL, Lear S,
487 Lichtenstein AH, Lobelo F, Morris PB, et al. Strategies for Promotion of a Healthy Lifestyle in

- 488 Clinical Settings: Pillars of Ideal Cardiovascular Health: A Science Advisory From the American
489 Heart Association. *Circulation*. 2021;CIR.0000000000001018.
- 490 40. Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in
491 Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. *JAMA*.
492 2020;324:1190–1200.
- 493 41. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, Zhang J, Tian M, Huang L, Li Z, et al. Effect of
494 Salt Substitution on Cardiovascular Events and Death. *N Engl J Med*. 2021;385:1067–1077.
- 495 42. Yin X, Paige E, Tian M, Li Q, Huang L, Yu J, Rodgers A, Elliott P, Wu Y, Neal B. The Proportion
496 of Dietary Salt Replaced With Potassium-Enriched Salt in the SSaSS: Implications for Scale-Up.
497 *Hypertension*. 2023;HYPERTENSIONAHA.122.20115.
- 498 43. Nutrition C for FS and A. Guidance for Industry: Voluntary Sodium Reduction Goals [Internet].
499 U.S. Food and Drug Administration. 2022 [cited 2023 Mar 17];Available from:
500 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-sodium-reduction-goals)
501 [voluntary-sodium-reduction-goals](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-sodium-reduction-goals)
- 502 44. Millett C, Lavery AA, Stylianou N, Bibbins-Domingo K, Pape UJ. Impacts of a National Strategy
503 to Reduce Population Salt Intake in England: Serial Cross Sectional Study. *PLOS ONE*.
504 2012;7:e29836.
- 505 45. Bell CN, Kerr J, Young JL. Associations between Obesity, Obesogenic Environments, and
506 Structural Racism Vary by County-Level Racial Composition. *Int J Environ Res Public Health*
507 [Internet]. 2019 [cited 2019 Apr 17];16. Available from:
508 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427384/>
- 509 46. Koohsari MJ, McCormack GR, Nakaya T, Oka K. Neighbourhood built environment and
510 cardiovascular disease: knowledge and future directions. *Nat Rev Cardiol*. 2020;17:261–263.
- 511 47. Step it Up! The Surgeon General’s Call to Action to Promote Walking and Walkable Communities.
- 512 48. CDC. Overcoming Barriers to Physical Activity [Internet]. Centers for Disease Control and
513 Prevention. 2022 [cited 2023 Jan 30];Available from:
514 <https://www.cdc.gov/physicalactivity/basics/adding-pa/barriers.html>
- 515 49. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health
516 inequities in the USA: evidence and interventions. *The Lancet*. 2017;389:1453–1463.
- 517 50. O’Neil CE, Nicklas TA, Keast DR, Fulgoni VL. Ethnic disparities among food sources of energy
518 and nutrients of public health concern and nutrients to limit in adults in the United States: NHANES
519 2003-2006. *Food Nutr Res*. 2014;58:15784.

520

521

522

It is made available under a [CC-BY 4.0 International license](#) .

523

524

Table 1. Characteristics of U.S. population aged 35-64 years with 2017 ACC/AHA stage 1 systolic hypertension recommended nonpharmacologic therapy,* NHANES years 2015-2018

Characteristics	Stage 1 systolic hypertension [†]	
	Men (N=152)	Women (N=186)
Age, years	47.0 (1.4)	50.4 (0.7)
Systolic BP, mmHg	133.6 (0.3)	133.7 (0.3)
Diastolic BP, mmHg	78.5 (0.9)	76.5 (0.9)
Predicted 10-year CVD risk, %	4.7 (0.4)	2.3 (0.2)
Non-pharmacological risk factors		
Overweight or obese, %	80.2	78.6
Physically inactive, %	29.9	44.8
High sodium intake, %	91.9	71.1
Low fruit and vegetable intake, %	57.4	62.6
High alcohol consumption, %	27.9	16.6
Healthcare access		
Health insurance type, %		
Public insurance	6.2	11.3
Private insurance	77.8	78.5
No insurance	16.0	10.2
Regular source of healthcare, %	71.3	82.9
Healthcare visits in past year, %		
None	32.5	11.6
One	19.4	28.3
Two or more	48.1	60.1

Values are mean (standard error) or %. Estimates calculated using survey sample weighting procedures on data collected from National Health and Nutrition Examination Survey years 2015-2018. N reflects the number of NHANES participants for each subgroup.

ACC = American College of Cardiology; AHA = American Heart Association; BP = blood pressure; NHANES – National Health and Nutrition Survey

*The 2017 ACC/AHA guideline defines stage 1 hypertension as having a systolic blood pressure of 130 to 139 mmHg or a diastolic blood pressure of 80 to 89 mmHg and recommends non-pharmacological BP management for those without diabetes, chronic kidney disease, or cardiovascular disease and less than 10% risk of a CVD event within 10 years calculated using the Pooled Cohort Risk Equations

[†] Stage 1 systolic hypertension defined as systolic BP ranging from 130 – 139 mmHg and diastolic BP < 90 mmHg

Table 2. Projected impact of controlling SBP to under 130 mmHg in adults with stage 1 hypertension recommended only nonpharmacologic therapy by the 2017 ACC/AHA BP guideline*, 2018-2027

Simulated target group	Population reached (millions)	Number of events prevented and healthcare costs saved (95% Confidence Intervals)				
		Incident CVD**	Total myocardial infarctions***	Total strokes***	CVD mortality	Healthcare cost savings ¥ (millions 2019 USD)
Men						
Full target population	4.2	15,300 (13,100 – 18,200)	4,100 (3,300 – 5,000)	5,400 (4,500 – 6,600)	1,600 (1,300 – 1,800)	\$955 (\$832 – \$1,131)
Subgroup with regular healthcare access	2.1	7,700 (6,600 – 9,200)	2,100 (1,700 – 2,500)	2,800 (2,300 – 3,400)	800 (700 – 900)	\$486 (\$423 – \$575)
Women						
Full target population	4.6	10,800 (9,500 – 12,500)	2,600 (2,200 – 3,100)	5,000 (4,200 – 6,000)	1,300 (1,100 – 1,500)	\$712 (\$624 – \$830)
Subgroup with regular healthcare access	3.4	8,100 (7,200 – 9,400)	2,000 (1,700 – 2,300)	3,800 (3,200 – 4,500)	1,000 (900 – 1,100)	\$534 (\$468 – \$621)

Values are numbers of events and healthcare costs when controlling systolic BP to 129 mmHg compared to status quo systolic BP over 10 years.

ACC = American College of Cardiology; AHA = American Heart Association; CVD = cardiovascular disease

*Simulations include those with systolic BP ranging from 130 to 139 mmHg, diastolic BP under 90 mmHg and no indicator of high CVD risk (diabetes, chronic kidney disease, cardiovascular disease, or $\geq 10\%$ predicted risk of a CVD event within 10 years)

**Includes myocardial infarction, cardiac arrest, angina, ischemic stroke and hemorrhagic stroke occurring in the CVD free population

***Includes myocardial infarction or ischemic stroke and hemorrhagic stroke occurring in the population with and without history of CVD

¥ Total healthcare costs are undiscounted and include costs from hospitalizations for MI, stroke, cardiac arrest, and revascularization procedures; chronic CVD outpatient care; and background costs for non-cardiovascular care

Table 3. Projected impact of evidence-based nonpharmacological therapy in adults with stage 1 hypertension by 2017 ACC/AHA BP guideline^a, 2018-2027

Simulated intervention*	Population reached (millions)	Number of events prevented and healthcare costs saved (95% Confidence Intervals)				
		Incident CVD **	Total myocardial infarctions***	Total stroke events***	CVD mortality	Healthcare costs savings¥ (millions 2019 USD)
DASH diet adherence	8.8	28,000 (18,100 – 38,400)	7,200 (4,600 – 10,000)	11,300 (7,200 – 15,500)	3,100 (2,000 – 4,200)	\$1,794 (\$1,191 – \$2,405)
Sustained weight loss	6.9	19,500 (15,200 – 24,200)	5,000 (3,800 – 6,300)	7,900 (5,900 – 10,000)	2,100 (1,600 – 2,600)	\$1,247 (\$987 – \$1,523)
Reduced sodium intake	7.1	17,900 (13,300 – 22,700)	4,600 (3,400 – 6,000)	7,100 (5,200 – 9,200)	1,900 (1,400 – 2,500)	\$1,141 (\$865 – \$1,434)
Increased fruit and vegetable intake	8.3	13,800 (3,400 – 23,000)	3,500 (1,000 – 5,900)	5,600 (1,500 – 9,300)	1,500 (400 – 2,500)	\$884 (\$287 – \$1,447)
Sufficient physical activity	3.3	7,200 (5,100 – 9,500)	1,800 (1,300 – 2,400)	3,000 (2,000 – 4,000)	800 (600 – 1,100)	\$461 (\$330 – \$596)
Moderated alcohol intake	1.9	3,700 (2,800 – 4,900)	1,000 (700 – 1,300)	1,500 (1,100 – 1,900)	400 (300 – 500)	\$239 (\$180 – \$308)

^a 2017 ACC/AHA BP guideline recommend only nonpharmacological therapy for those with SBP ranging from 130 to 139 mmHg, diastolic BP under 90 mmHg and no indicator of high CVD risk (diabetes, chronic kidney disease, cardiovascular disease, or $\geq 10\%$ predicted risk of a CVD event within 10 years)

*Each estimate reflects contrasts in outcomes between SBP reductions due to the simulated intervention and no change in systolic BP among the target population. Interventions were applied only to adults in the target population whose health behaviors fall below recommended thresholds. The DASH diet intervention applied to the full target population; the sustained weight loss intervention applied adults who are overweight or obese; the dietary sodium intervention applied to adults currently consuming excessive sodium; the physical activity intervention applied to adults who engage in insufficient weekly metabolic equivalents of task; and the alcohol reduction intervention applied to adults currently consuming higher than recommended amounts of alcohol daily.

**Incident CVD includes myocardial infarction, cardiac arrest, angina, ischemic and hemorrhagic stroke occurring in the CVD free population

***Includes myocardial infarction or ischemic stroke and hemorrhagic stroke occurring in the population with and without history of

CVD

¥ Total healthcare costs are undiscounted and include costs from hospitalizations for MI, stroke, cardiac arrest, and revascularization procedures; chronic CVD outpatient care; and background costs for non-cardiovascular care

Figure 1. Projected 10-year reduction in incident cardiovascular disease events for evidence-based non-pharmacological approaches to reducing blood pressure among adults with and without self-reported regular healthcare utilization. Simulations

targeted adults with stage 1 systolic hypertension (SBP 130 – 139 mmHg and DBP <90) who qualify for nonpharmacological therapy in the 2017 ACC/AHA guidelines. We simulated effect of the DASH diet in those not currently eating a DASH dietary pattern (assumed to be everyone in the target population), sustained weight loss in adults who are overweight or obese (80% of men and 79% of women), reduced sodium intake in those currently consuming ≥ 2300 mg/day (92% of men and 71% of women), increasing fruit and vegetable intake in those not currently eating at least 2.5 cups of vegetables and 2 cups of fruit per day (94% of men and 96% of women), sufficient physical activity for inactive adults (<600 weekly metabolic physical equivalents of task; 30% of men and 45% of women), and reductions in alcohol intake for men and women drinking more than 2 or 1 drink per day, respectively (28% of men and 17% of women). 49% of men and 27% of women reported not having regular healthcare: i.e., being uninsured, not having a routine place to receive healthcare, or not visiting a healthcare professional in a non-emergency room context in the previous 12 months.

